Evidence map›Paper›PMID 41635304›Full record

ArticleBiosafety and health2025

Computational optimization of a pan-coronavirus fusion inhibitory peptide targeting spike's heptapeptide repeat region.

Peixiang Gao, Shuo Liu, Xiaojing Chi, Xinhui Zhang, Xiuying Liu, Xuehua Yang, Huarui Duan, Jingya Zhou, Weijin Huang, Wei Yang

Abstract read
In one paragraph

Article in Biosafety and health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Peixiang GaoKey Laboratory of Pathogen Infection Prevention and Control (Ministry of Education), National Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 102629, China.
Shuo LiuChinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China.
Xiaojing ChiKey Laboratory of Pathogen Infection Prevention and Control (Ministry of Education), National Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 102629, China.
Xinhui ZhangKey Laboratory of Pathogen Infection Prevention and Control (Ministry of Education), National Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 102629, China.
Xiuying LiuKey Laboratory of Pathogen Infection Prevention and Control (Ministry of Education), National Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 102629, China.
Xuehua YangKey Laboratory of Pathogen Infection Prevention and Control (Ministry of Education), National Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 102629, China.
Huarui DuanKey Laboratory of Pathogen Infection Prevention and Control (Ministry of Education), National Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 102629, China.
Jingya ZhouKey Laboratory of Pathogen Infection Prevention and Control (Ministry of Education), National Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 102629, China.
Weijin HuangDivision of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), State Key Laboratory of Drug Regulatory Science, Beijing 102629, China.
Wei YangKey Laboratory of Pathogen Infection Prevention and Control (Ministry of Education), National Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 102629, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the past two decades, highly pathogenic coronaviruses (CoVs), such as severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have constituted a grave threat to human health. Broad-spectrum anti-CoV fusion inhibitors that target the heptapeptide repeat (HR) region within the S2 subunit of SARS-CoV-2 spike (S) protein exhibit inhibitory activity against various CoVs. In this study, we employed EK1, a fusion inhibitor previously characterized for its broad spectrum and potent antiviral activity, as a scaffold for computational design to enhance its inhibitory potential using the Rosetta software suite. We designed EK1 variants and synthesized two N-terminally extended EK1 elongation peptides, and evaluated their inhibitory activity. The results revealed that the designed peptides enhanced inhibitory activity against diverse CoVs. Structural analysis and molecular dynamics simulations demonstrated that EK1 variants formed more robust interactions with HR1 of SARS-CoV-2, and these interactions were conserved across different CoVs. These findings underscore the utility of computational approaches in optimizing therapeutic peptides.

Indexed as

Computational designCoronaviruses (CoVs)Fusion inhibitorsSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Identifiers

PMID41635304
PMCPMC12861747

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.